Albireo Pharma Inc Anno IPO
Cos'è Anno IPO di Albireo Pharma Inc?
Anno IPO di Albireo Pharma Inc è 2016
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su NASDAQ rispetto a Albireo Pharma Inc
Cosa fa Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Aziende con anno ipo simili a Albireo Pharma Inc
- The Toronto-Dominion Bank PFD SER 9 3.7% ha Anno IPO di 2015
- Fura Gems ha Anno IPO di 2015
- Hostess Brands ha Anno IPO di 2015
- Nabriva Therapeutics Plc ha Anno IPO di 2015
- REF ha Anno IPO di 2015
- H-Source ha Anno IPO di 2015
- Albireo Pharma Inc ha Anno IPO di 2016
- American Pacific Borates ha Anno IPO di 2017
- Razer ha Anno IPO di 2017
- DEAG Deutsche Entertainment Aktiengesellschaft ha Anno IPO di 2017
- Hamilton Beach Brands Co ha Anno IPO di 2017
- Artelo Biosciences ha Anno IPO di 2017
- VARTA AG ha Anno IPO di 2017